ACELRX PHARMACEUTICALS INC Form 8-K January 08, 2016 **UNITED STATES**

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2016

ACELRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE001-3506841-2193603(State of incorporation)(Commission File No.)(IRS Employer Identification No.)

351 Galveston Drive

Redwood City, CA 94063

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (650) 216-3500

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Item 8.01. Other Events.

On January 8, 2016, AcelRx Pharmaceuticals, Inc. issued a press release entitled "AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for ZalvisoTM in 1Q 2016," a copy of which is attached as Exhibit 99.1 to this Report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Description Number

99.1 Press Release dated January 8, 2016.

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Signatures

Date: January 8, 2016

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACELRX PHARMACEUTICALS, INC.

By:

/s/ Jane Wright-Mitchell Jane Wright-Mitchell Chief Legal Officer

INDEX TO EXHIBITS

Exhibit Number	Description
	Press
	Release
99.1	dated
	January 8.

January 8, 2016.